Entrada Therapeutics has officially launched clinical trials in Europe for its innovative exon skipping therapies targeting Exon 44 and Exon 45—marking a significant milestone in the treatment of Duchenne muscular dystrophy (DMD).
These investigational therapies are designed to address specific genetic mutations in DMD patients, with the goal of restoring dystrophin production and improving clinical outcomes. The start of these trials highlights Entrada’s commitment to advancing precision genetic medicine and expanding global access to novel treatments for rare neuromuscular diseases. – Read More: What is Exon Skipping and How does it Work? –
Table of Contents
Entrada Exon 44 Skipping – NCT07037862 –
This is a study of the investigational medicine ENTR-601-44 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition.
Study Start (Estimated): 2025-06-30
Primary Completion (Estimated): 2029-03-28
Study Completion (Estimated): 2029-03-28
Number of Participants (Estimated): 24
Locations: Belgium, Italy, Spain, United Kingdom.
Ages Eligible for Study: 4 Years to 20 Years (Child, Adult)
Principal inclusion and exclusion criteria. – NCT07037862 –
Entrada Exon 45 Skipping – NCT07038824 –
This is a study of the investigational medicine ENTR-601-45 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition.
Study Start (Estimated): 2025-09-30
Primary Completion (Estimated): 2029-03-01
Study Completion (Estimated): 2029-03-01
Number of Participants (Estimated): 24
Locations: Belgium, Italy, Netherlands, Spain, United Kingdom.
Ages Eligible for Study: 4 Years to 20 Years (Child, Adult)
Principal inclusion and exclusion criteria. – NCT07038824 –
Read more about Entrada Therapeutics.
